1-甲基-1,2,3-苯并三唑-5-甲醛 | 499770-67-1

• 物质功能分类: 医药中间体
• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并三唑类
• 中文名称: 1-甲基-1,2,3-苯并三唑-5-甲醛
• 中文别名: 1-甲基-1H-1,2,3-苯并噻唑-5-甲醛
• 英文名称: 1-methyl-1H-benzo[d][1,2,3]triazole-5-carbaldehyde
• 英文别名: 1-methyl-1H-1,2,3-benzotriazole-5-carbaldehyde；1-methyl-1H-benzo[d]triazole-5-carbaldehyde；1-methyl-1H-benzotriazole-5-carbaldehyde；1-methyl-1H-benzotriazole-5-carboxaldehyde；1-methylbenzotriazole-5-carbaldehyde
• CAS: 499770-67-1
• 化学式: C₈H₇N₃O
• mdl: MFCD03407337
• 分子量: 161.163
• InChiKey: IPVPVOVAJDRRAK-UHFFFAOYSA-N

物化性质

• 熔点：
  162 °C
• 沸点：
  354.1±15.0 °C(Predicted)
• 密度：
  1.33±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  0.6
• 重原子数：
  12
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.125
• 拓扑面积：
  47.8
• 氢给体数：
  0
• 氢受体数：
  3

安全信息

• 危险品标志：
  Xn
• 安全说明：
  S26,S36/37/39
• 危险类别码：
  R20/21/22,R36/37/38
• 海关编码：
  2933990090
• 危险性防范说明：
  P261,P280,P305+P351+P338
• 危险性描述：
  H302,H315,H319,H332,H335

SDS

Name:	1-Methyl-1h-1 2 3-benzotriazole-5-carbaldehyde 90+% Material Safety Data Sheet
Synonym:
CAS:	499770-67-1

Section 1 - Chemical Product MSDS Name:1-Methyl-1h-1 2 3-benzotriazole-5-carbaldehyde 90+% Material Safety Data Sheet
Synonym:

---

Section 2 - COMPOSITION, INFORMATION ON INGREDIENTS

CAS#	Chemical Name	content	EINECS#
499770-67-1	1-Methyl-1H-1,2,3-benzotriazole-5-carb	90+%	unlisted

Hazard Symbols: XN
Risk Phrases: 20/21/22 36/37/38

---

Section 3 - HAZARDS IDENTIFICATION
EMERGENCY OVERVIEW
Harmful by inhalation, in contact with skin and if swallowed.
Irritating to eyes, respiratory system and skin.
Potential Health Effects
Eye:
Causes eye irritation.
Skin:
Causes skin irritation. Harmful if absorbed through the skin.
Ingestion:
Harmful if swallowed. May cause irritation of the digestive tract.
Inhalation:
Harmful if inhaled. Causes respiratory tract irritation.
Chronic:
Not available.

---

Section 4 - FIRST AID MEASURES
Eyes: Flush eyes with plenty of water for at least 15 minutes, occasionally lifting the upper and lower eyelids. Get medical aid.
Skin:
Get medical aid. Flush skin with plenty of water for at least 15 minutes while removing contaminated clothing and shoes.
Ingestion:
Get medical aid. Wash mouth out with water.
Inhalation:
Remove from exposure and move to fresh air immediately. If not breathing, give artificial respiration. If breathing is difficult, give oxygen. Get medical aid.
Notes to Physician:

---

Section 5 - FIRE FIGHTING MEASURES
General Information:
As in any fire, wear a self-contained breathing apparatus in pressure-demand, MSHA/NIOSH (approved or equivalent), and full protective gear.
Extinguishing Media:
Use water spray, dry chemical, carbon dioxide, or chemical foam.

---

Section 6 - ACCIDENTAL RELEASE MEASURES
General Information: Use proper personal protective equipment as indicated in Section 8.
Spills/Leaks:
Vacuum or sweep up material and place into a suitable disposal container.

---

Section 7 - HANDLING and STORAGE
Handling:
Avoid breathing dust, vapor, mist, or gas. Avoid contact with skin and eyes.
Storage:
Store in a cool, dry place. Store in a tightly closed container.
Store under nitrogen.

---

Section 8 - EXPOSURE CONTROLS, PERSONAL PROTECTION
Engineering Controls:
Facilities storing or utilizing this material should be equipped with an eyewash facility and a safety shower. Use adequate ventilation to keep airborne concentrations low.
Exposure Limits CAS# 499770-67-1: Personal Protective Equipment Eyes: Not available.
Skin:
Wear appropriate protective gloves to prevent skin exposure.
Clothing:
Wear appropriate protective clothing to prevent skin exposure.
Respirators:
Follow the OSHA respirator regulations found in 29 CFR 1910.134 or European Standard EN 149. Use a NIOSH/MSHA or European Standard EN 149 approved respirator if exposure limits are exceeded or if irritation or other symptoms are experienced.

---

Section 9 - PHYSICAL AND CHEMICAL PROPERTIES

Physical State: Solid
Color: off-white
Odor: Not available.
pH: Not available.
Vapor Pressure: Not available.
Viscosity: Not available.
Boiling Point: Not available.
Freezing/Melting Point: 159 - 162 deg C
Autoignition Temperature: Not available.
Flash Point: Not available.
Explosion Limits, lower: Not available.
Explosion Limits, upper: Not available.
Decomposition Temperature:
Solubility in water:
Specific Gravity/Density:
Molecular Formula: C8H7N3O
Molecular Weight: 161.16

---

Section 10 - STABILITY AND REACTIVITY
Chemical Stability:
Not available.
Conditions to Avoid:
Incompatible materials.
Incompatibilities with Other Materials:
Oxidizing agents, reducing agents.
Hazardous Decomposition Products:
Nitrogen oxides, carbon monoxide, carbon dioxide.
Hazardous Polymerization: Has not been reported

---

Section 11 - TOXICOLOGICAL INFORMATION
RTECS#:
CAS# 499770-67-1 unlisted.
LD50/LC50:
Not available.
Carcinogenicity:
1-Methyl-1H-1,2,3-benzotriazole-5-carbaldehyde - Not listed by ACGIH, IARC, or NTP.

---

Section 12 - ECOLOGICAL INFORMATION

---

Section 13 - DISPOSAL CONSIDERATIONS
Dispose of in a manner consistent with federal, state, and local regulations.

---

Section 14 - TRANSPORT INFORMATION

IATA
Shipping Name: TOXIC SOLID, ORGANIC, N.O.S.*
Hazard Class: 6.1
UN Number: 2811
Packing Group: III
IMO
Shipping Name: TOXIC SOLID, ORGANIC, N.O.S.
Hazard Class: 6.1
UN Number: 2811
Packing Group: III
RID/ADR
Shipping Name: TOXIC SOLID, ORGANIC, N.O.S.
Hazard Class: 6.1
UN Number: 2811
Packing group: III

---

Section 15 - REGULATORY INFORMATION

European/International Regulations
European Labeling in Accordance with EC Directives
Hazard Symbols: XN
Risk Phrases:
R 20/21/22 Harmful by inhalation, in contact with
skin and if swallowed.
R 36/37/38 Irritating to eyes, respiratory system
and skin.
Safety Phrases:
S 26 In case of contact with eyes, rinse immediately
with plenty of water and seek medical advice.
S 36/37/39 Wear suitable protective clothing, gloves
and eye/face protection.
WGK (Water Danger/Protection)
CAS# 499770-67-1: No information available.
Canada
None of the chemicals in this product are listed on the DSL/NDSL list.
CAS# 499770-67-1 is not listed on Canada's Ingredient Disclosure List.
US FEDERAL
TSCA
CAS# 499770-67-1 is not listed on the TSCA inventory.
It is for research and development use only.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

制备方法与用途

用途

1-甲基-1,2,3-苯并三唑-5-甲醛是一种有机中间体。其制备过程首先从苯并三唑-5-羧酸甲酯出发，制备出1-甲基-3H-苯并三唑-5-羧酸甲酯，随后通过还原和氧化步骤得到目标化合物1-甲基-1,2,3-苯并三唑-5-甲醛。

反应信息

• 作为反应物：
  描述：

  1-甲基-1,2,3-苯并三唑-5-甲醛 在 chloro(1,5-cyclooctadiene)rhodium(I) dimer 、 potassium tert-butylate 、 三乙胺 作用下， 以 四氢呋喃 、 1,4-二氧六环 、 水 为溶剂， 反应 3.5h， 生成 methyl 3-(3-(hydroxymethyl)-4-methylphenyl)-3-(1-methyl-1H-benzo[d][1,2,3]triazol-5-yl)propanoate
  参考文献：
  名称：

  [EN] NRF2 REGULATORS
  [FR] RÉGULATEURS DE NRF2

  摘要：

  这项发明涉及双芳基类似物，含有它们的药物组合物以及它们作为Nrf2调节剂的用途。

  公开号：

  WO2015092713A1
• 作为产物：
  描述：

  4-羟基-3,5-二碘苯甲酸甲酯 在 potassium fluoride 、 lithium chloro-isopropyl-magnesium chloride 、 三甲基氯硅烷 、 palladium 10% on activated carbon 、 异丙基氯化镁 、 二异丁基氢化铝 、 对甲苯磺酸 、 三乙胺 、 sodium iodide 作用下， 以 四氢呋喃 、 甲醇 、 乙醚 、 二氯甲烷 、 丙酮 、 乙腈 为溶剂， 反应 80.08h， 生成 1-甲基-1,2,3-苯并三唑-5-甲醛
  参考文献：
  名称：

  芳基和甲硅烷基苯并与1，3-偶极的区域互补环加成反应：苯并咪唑衍生物的选择性合成

  摘要：

  苯并稠合的含氮杂环在生物活性化合物中含量很高。制备此类杂环的最重要方法之一是苯与1，3-偶极化合物的（3 + 2）环加成反应。但是，不对称取代的苯炔的反应通常显示出低选择性，因此产生两种区域异构体的混合物。在本文中，我们描述了多取代的苯并稠合的唑衍生物如苯并三唑，1 H-吲唑和苯并[ d]的两种区域异构体的合成。异恶唑通过3-硼基和3-甲硅烷基苯并与1,3-偶极的区域互补（3 + 2）环加成反应。从新的前体中生成3-硼基苯甲酮的改进是这项工作最重要的结果之一，该工作成功进行了（3 + 2）个环加成反应，并具有排他性和近端选择性。另一方面，3-甲硅烷基苯甲酮的类似反应选择性地提供了远端的环加合物。通过密度泛函理论计算对这些惊人的区域选择性的反应途径进行分析，结果表明，硼烷基苯甲酮的（3 + 2）环加成反应受硼烷基的静电作用控制，而甲硅烷基苯甲酮的环加成反应主要受大体积立体位阻的控制。通过异常过渡态产生静电不利的加合物的甲硅烷基。

  DOI：

  10.1021/jo302802b

文献信息

• Substituted Spiro-amide Compounds
  申请人：Schunk Stefan

  公开号：US20100249095A1

  公开（公告）日：2010-09-30

  Substituted spiro-amide compounds corresponding to formula I in which R5 through R8, D, X, Y and Z have defined meanings, processes for preparing such spiro-amide compounds, pharmaceutical compositions containing such compounds, and methods of using such spiro-amide compounds for treating and/or inhibiting disorders or disease states mediated at least in part by the bradykinin 1 receptor.

  将与式I相对应的螺环酰胺化合物替代为R5至R8、D、X、Y和Z具有定义含义的过程，用于制备这种螺环酰胺化合物，含有这种化合物的药物组合物，以及使用这种螺环酰胺化合物治疗和/或抑制至少部分由激肽酶1受体介导的疾病或疾病状态的方法。
• Novel benzotriazoles anti-inflammatory compounds
  申请人：Pfizer Inc.

  公开号：US20030078432A1

  公开（公告）日：2003-04-24

  The present invention relates to novel benzotriazoles of the formula I 1 wherein Het is an optionally substituted 5-membered heterocycle containing one to two heteroatoms selected from nitrogen, sulfur and oxygen wherein at least one of said heteroatoms atoms must be nitrogen; R 2 is selected from the group consisting of hydrogen, (C 1 -C 6 )alkyl or other suitable substituents; R 3 is selected from the group consisting of hydrogen, (C 1 -C 6 )alkyl or other suitable substituents; s is an integer from 0-5; to intermediates for their preparation, to pharmaceutical compositions containing them and to their medicinal use. The compounds of the present invention are potent inhibitors of MAP kinases, preferably p38 kinase. They are useful in the treatment of inflammation, osteoarthritis, rheumatoid arthritis, cancer, repurfusion or ischemia in stroke or heart attack, autoimmune diseases and other disorders.

  本发明涉及公式I的新型苯并三唑 其中Het是一个可选择取代的含有一个到两个来自氮、硫和氧的杂原子的5元杂环，其中至少一个杂原子必须是氮; R 2 选自由氢、(C 1 -C 6 )烷基或其他适当的取代基组成的群; R 3 选自由氢、(C 1 -C 6 )烷基或其他适当的取代基组成的群; s是0-5之间的整数; 用于它们的制备的中间体，含有它们的药物组合物以及它们的药用。本发明的化合物是MAP激酶，优选p38激酶的有效抑制剂。它们在治疗炎症、骨关节炎、类风湿性关节炎、癌症、中风或心脏病发作中的再灌注或缺血、自身免疫疾病和其他疾病中有用。
• [EN] AZOLIDINONE-VINYL FUSED-BENZENE DERIVATIVES<br/>[FR] DERIVES DE BENZENE A FUSION AZOLIDINONE-VINYLE
  申请人：APPLIED RESEARCH SYSTEMS

  公开号：WO2004007491A1

  公开（公告）日：2004-01-22

  The present invention is related to azolidinedione-vinyl fused-benzene derivatives of formula (I) for the treatment and/or prophylaxis of autoimmune disorders and/or inflammatory diseases, cardiovascular diseases, neurodegenerative diseases, bacterial or viral infections, kidney diseases, platelet aggregation, cancer, graft rejection or lung injuries. Formula (I), wherein A, X, Y, Z, R1 , R2 and n are as described in the description.

  本发明涉及式(I)的噁唑烷二酮-乙烯融合苯衍生物，用于治疗和/或预防自身免疫性疾病和/或炎症性疾病、心血管疾病、神经退行性疾病、细菌或病毒感染、肾脏疾病、血小板聚集、癌症、移植排斥或肺部损伤。式(I)中，A、X、Y、Z、R1、R2和n如描述中所述。
• [EN] DIAZEPANES AS HISTAMINE H3 RECEPTOR ANTAGONISTS<br/>[FR] DIAZÉPANES, ANTAGONISTES DU RÉCEPTEUR H3 DE L'HISTAMINE
  申请人：EVOTEC NEUROSCIENCES GMBH

  公开号：WO2009095394A1

  公开（公告）日：2009-08-06

  The invention relates to compounds of formula (I) wherein R1 to R8 and X1, X2 have the meaning as cited in the description and the claims. Said compounds are useful as Histamine H3 receptor antagonists. The invention also relates to pharmaceutical compositions, the preparation of such compounds as well as the production and use as medicament.

  该发明涉及式(I)的化合物，其中R1至R8和X1、X2的含义如描述和权利要求中所述。所述化合物可用作组胺H3受体拮抗剂。该发明还涉及制药组合物，制备此类化合物以及作为药物的生产和使用。
• PDE10 INHIBITORS AND RELATED COMPOSITIONS AND METHODS
  申请人：Cutshall Neil S.

  公开号：US20110224202A1

  公开（公告）日：2011-09-15

  Compounds that inhibit PDE10 are disclosed that have utility in the treatment of a variety of conditions, including (but not limited to) psychotic, anxiety, movement disorders and/or neurological disorders such as Parkinson's disease, Huntington's disease, Alzheimer's disease, encephalitis, phobias, epilepsy, aphasia, Bell's palsy, cerebral palsy, sleep disorders, pain, Tourette's syndrome, schizophrenia, delusional disorders, drug-induced psychosis and panic and obsessive-compulsive disorders. Pharmaceutically acceptable salts, stereoisomers, solvates and prodrugs of the compounds are also provided. Also disclosed are compositions containing a compound in combination with a pharmaceutically acceptable carrier, as well as methods relating to the use thereof for inhibiting PDE10 in a warm-blooded animal in need of the same.

  揭示了抑制PDE10的化合物，对治疗多种疾病有用，包括（但不限于）精神病、焦虑、运动障碍和/或神经系统疾病，如帕金森病、亨廷顿病、阿尔茨海默病、脑炎、恐惧症、癫痫、失语症、贝尔氏面瘫、脑瘫、睡眠障碍、疼痛、抽动综合征、精神分裂症、妄想症、药物诱发的精神病、恐慌和强迫症。还提供了这些化合物的药用盐、立体异构体、溶剂合物和前药。还揭示了含有化合物与药用载体组合的组合物，以及与使用有关的方法，用于在需要的温血动物中抑制PDE10。